By Mill Chart
Last update: Apr 29, 2024
Monday's session: top gainers and losers
Ticker | Change | Comment |
---|---|---|
ANVS | -53.58% | There was a downturn in ANNOVIS BIO's (NYSE:ANVS) shares, as they experienced a 53.58% decline, closing at $8.36 during Monday's session. A press release (Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease) was released earlier today. |
SWVLW | -29.41% | There was a downturn in PIVOTAL HOLDINGS CORP -CW27's (NASDAQ:SWVLW) shares, as they experienced a 29.41% decline, closing at $0.01 during Monday's session. Shareholders saw the stock price going 57.73% higher in the past 3 months. |
JAN | -26.67% | JANONE INC's (NASDAQ:JAN) stock price faced a 26.67% decline, reaching $3.74 during Monday's session. In the last month the share price increased with 93.92%. |
MBIO | -25.66% | There was a notable decline in MUSTANG BIO INC's (NASDAQ:MBIO) shares, as they dropped 25.66% to $0.23 during Monday's session. In the last month the share price dropped with 69.61%. |
TCJH | -23.71% | Investors witnessed a 23.71% drop in TOP KINGWIN LTD-A's (NASDAQ:TCJH) stock price, which closed at $0.68 during Monday's session. The stock is trading 42.01% lower than a month ago. |
FTEL | -23.62% | FITELL CORP's (NASDAQ:FTEL) shares fell 23.62% to $6.11. The stock is trading 183.0% higher than 3 months ago. |
ATXI | -22.18% | AVENUE THERAPEUTICS INC's (NASDAQ:ATXI) stock price faced a 22.18% decline, reaching $4.83 during Monday's session. Earlier today the company had a press release: Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds. |
CJJD | -18.73% | CHINA JO-JO DRUGSTORES HOLDI's (NASDAQ:CJJD) stock price faced a 18.73% decline, reaching $2.3 during Monday's session. Shareholders saw the stock price going 22.44% lower in the past 3 months. |
ISUN | -17.56% | ISUN INC's (NASDAQ:ISUN) stock price encountered a 17.56% decline, reaching $0.14 during Monday's session. Shareholders saw the stock price going 32.8% lower in the past month. |
IONM | -17.46% | The market experienced a 17.46% downturn in ASSURE HOLDINGS CORP's (NASDAQ:IONM) stock price, closing at $0.58 during Monday's session. Shareholders saw the stock price going 42.07% higher in the past month. |
For the full top loser list go to our top losers page.
MUSTANG BIO INC
NASDAQ:MBIO (5/17/2024, 7:12:09 PM)
After market: 0.3192 +0.01 (+2.31%)0.312
+0.01 (+3.97%)
MBIO stock results show that Mustang Bio beat analyst estimates for earnings per share the first quarter of 2024.
Potential Additional Gross Proceeds Upon Cash Exercise of Warrants of Up to $12 Million...
WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical...
Monday's session: top gainers and losers
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.
Planning for proof-of concept Phase 1 investigator-sponsored clinical trial evaluating MB-106 CD20-targeted CAR T-cell therapy in autoimmune diseases is...
WORCESTER, Mass., March 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers and rare genetic diseases, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.
We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Pre-market stock movers are worth checking out on Thursday to get an idea of the hottest stocks worth watching this morning!
MB-101 was well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+...
WORCESTER, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical...
Mustang Bio files prospectus for resale of 2.74 million common shares; this document is not an offer to sell these securities.